10-K: Stimcell Energetics Faces Financial Strain in FY26 10-K

Stimcell Energetics Inc. reported a significant increase in net loss and operating expenses for the fiscal year ended May 31, 2026, while continuing to generate no revenue, highlighting ongoing financial challenges and a substantial working capital deficit.

Summary

• Stimcell Energetics Inc. reported a net loss of $895,375 for the fiscal year ended May 31, 2026, an increase of 58.1% from the previous year's loss of $566,293.
• Total operating expenses rose by 58.2% to $826,027 in fiscal year 2026, driven primarily by a 79.2% increase in general and administrative expenses and a 226.8% surge in research and development costs.
• The company generated no revenue in fiscal years 2025 and 2026, with no current revenue-generating activities associated with its eBalance Systems.
• As of May 31, 2026, the company had a working capital deficit of $1,811,320, an increase of 45.3% from the prior year.
• The company's ability to continue as a going concern is subject to substantial doubt due to its accumulated deficit of $11,756,931 and its reliance on future financing.
• Significant related-party debt remains a concern, with amounts due to related parties totaling $1,498,798 as of May 31, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's continued lack of revenue, significant net losses, working capital deficiency, and substantial related-party debt, all of which raise serious going concern issues.

Positives

• The company is actively redesigning its eBalance Home device into a more compact and affordable consumer unit, with engagement of ADM Tronics Unlimited, Inc. for engineering expertise.
• The eBalance trademark has been registered in Canada, the European Union, the UK, and the United States.
• The company's audit committee has been established and is functioning, with two independent members and financial experts.

Negatives

• The company reported a net loss of $895,375 for the fiscal year ended May 31, 2026, a significant increase from the prior year.
• Operating expenses increased by 58.2% to $826,027 in fiscal year 2026.
• General and administrative expenses increased by 79.2% to $382,560, largely due to a $142,787 increase in corporate communications.
• Research and development costs surged by 226.8% to $209,176, driven by the redesign of the eBalance Home device.
• The company generated no revenue in fiscal years 2025 and 2026.
• A working capital deficit of $1,811,320 exists as of May 31, 2026.
• The company has an accumulated deficit of $11,756,931 since inception.
• Substantial related-party debt of $1,498,798 is outstanding as of May 31, 2026.

Risks

• The company operates in a highly competitive market and faces competition from large, well-established medical device manufacturers and pharmaceutical companies.
• The company is subject to numerous governmental regulations, and the process of obtaining regulatory approvals can be costly and time-consuming.
• Inability to protect and enforce intellectual property rights could adversely affect financial results.
• Research and development efforts may not result in commercially successful products.
• Significant safety concerns could arise for the company's products.
• Inability to attract and maintain key personnel may cause the company's business to fail.
• The company has a limited operating history and has generated only minimal revenues to date, with expected continued financial losses.
• The company needs to acquire additional financing, or its business will fail, with substantial doubt raised about its ability to continue as a going concern.

Future Outlook

Management expects elevated research and development expenditures to continue in the near term as development progresses on the redesigned eBalance Home device. The company's continuation as a going concern depends on obtaining additional financing and achieving profitable operations.

Management Comments

• Management expects elevated research and development expenditures to continue in the near term as development progresses.
• Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
• The company's continuation as a going concern depends upon the continued financial support of its shareholders, its ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations.

Industry Context

StockSavvy.ai notes that Stimcell Energetics operates in the highly competitive biotech and medical device sector, particularly focusing on diabetes and pain management. The company's reliance on microcurrent therapy, which is not yet widely accepted in traditional medicine, presents both a unique market opportunity and a significant hurdle for market penetration and regulatory approval.

Comparison to Industry Standards

• The company's lack of revenue and significant net losses are not in line with established medical device companies that have successfully navigated regulatory pathways and achieved commercial sales.
• The substantial working capital deficit and accumulated deficit are indicative of a company in a precarious financial position, unlike industry leaders who typically maintain stronger balance sheets to fund ongoing R&D and market expansion.
• The reliance on related-party financing and the ongoing need for additional capital are common in early-stage biotech but highlight a higher risk profile compared to companies with diversified funding sources or established revenue streams.

Legal Proceedings

• The Company is not a party to any pending legal proceedings.

Related Party Transactions

• Amounts due to related parties totaled $665,321 as of May 31, 2026, including amounts due to the CEO, CFO, and an entity controlled by a director.
• Notes and advances due to related parties totaled $833,477 as of May 31, 2026, including significant amounts due to Richard Jeffs, David Jeffs, Amir Vahabzadeh, Sam Ahdoot, and Susan Jeffs, with various interest rates and terms.
• Management fees of $90,000 were incurred to the CEO, President, and Director.
• Consulting fees of $30,000 were incurred to the CFO.
• Consulting fees of $108,790 were incurred to an entity controlled by a director.

Stakeholder Impact

• Shareholders face significant dilution risk due to the company's need to raise additional capital through future stock offerings and potential conversion of debt into equity.
• Existing shareholders may experience a decrease in the percentage ownership of their investment due to potential future share issuances.
• Creditors and lenders, particularly related parties, face uncertainty regarding the repayment of outstanding debt given the company's financial condition and going concern issues.
• Employees (executive officers acting as consultants) are compensated through monthly fees, but the company's financial stability impacts job security.

Next Steps

• Continue redesign of the eBalance Home device into a compact, affordable consumer unit optimized for home use.
• Seek additional equity or debt financing to support operations and device redesign.
• Potentially pursue FDA approval for future products or indications.
• Conduct future clinical trials to further investigate the eBalance Systems' efficacy.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, increasing losses, a significant working capital deficit, and substantial related-party debt, raising serious going concern doubts. The lack of progress in commercialization and reliance on future, uncertain financing make it a high-risk investment.

Keywords

eBalance Technology, microcurrent therapy, diabetes management, pain management, biotech, medical device, research and development, financial condition